| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -21.3 | -19.0 |
| Net income | -21.3 | -19.0 |
| EPS (diluted, $ a share) | $-1.08 | $-1.02 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: TECX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Tectonic Therapeutic, Inc.: key numbers
- Share price
- $20.98Close, Nov 16
- Market cap
- $419M
- Shares outstanding
- 19.95MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Tectonic Therapeutic, Inc.
All →Tectonic Therapeutic Financial Results
Tectonic Therapeutic reported Q3 2026 financial results, ending the period with $234.7 million in cash which is expected to fund operations into Q1 2029. The company highlighted clinical progress, including favorable Phase 1a results for TX2100 and the dosing of the first patient in the Phase 2a ALPINE trial for TX45. Topline results for the APEX Phase 2 trial in PH-HFpEF are anticipated by the end of January 2027.
- Term
- Q3 2026
“The favorable safety, tolerability and PK results from the single ascending-dose portion of our TX2100 Phase 1a trial in healthy adult volunteers, together with FDA Fast Track designation for HHT and IND clearance for our Phase 1b trial, support our plans to evaluate TX2100 in patients with HHT.”
Alise Reicin, M.D., President and Chief Executive Officer
“We plan to initiate an open-label Phase 1b trial in patients with hematologic-support-dependent HHT by year-end 2026 and, in parallel, a placebo-controlled Phase 2 trial in patients with moderate-to-severe HHT in early 2027. We are also approaching a critical milestone for TX45, with topline results from our APEX Phase 2 trial in PH-HFpEF anticipated by the end of January 2027.”
Alise Reicin, M.D., President and Chief Executive Officer
Tectonic Therapeutic CSO Peter McNamara Sells $12.3K of Stock
Peter McNamara, CSO, sold 536 shares of Tectonic Therapeutic, Inc. at $23.04 a share, worth $12.3K in total on Sep 30, 2026. Shares held after the trade: 54,305 (-1.0%).
- Value
- $12.3K
- Shares
- 536
- Price
- $23.04
- Role
- CSO
- Holding change
- -1.0%
- Trade date
- Sep 30, 2026
Tectonic Therapeutic Clinical Trial Data
Tectonic Therapeutic announced favorable topline results from its Phase 1a clinical trial of TX2100, demonstrating that single ascending doses were generally safe and well-tolerated in healthy volunteers. The company also received FDA Fast Track designation and IND clearance to proceed with Phase 1b and Phase 2 trials in patients with Hereditary Hemorrhagic Telangiectasia (HHT).